These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8201762)

  • 21. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
    Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
    [No Abstract]   [Full Text] [Related]  

  • 22. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing.
    Levine JM; Noecker RJ; Lane LC; Snyder RW; Rapedius M; Blanchard J
    J Ocul Pharmacol Ther; 2004 Jun; 20(3):210-6. PubMed ID: 15279726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion of levofloxacin into bone and synovial tissues.
    Rimmelé T; Boselli E; Breilh D; Djabarouti S; Bel JC; Guyot R; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2004 Mar; 53(3):533-5. PubMed ID: 14963066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Critical appraisal of air pouch infection model in rats.
    Saribas Z; Ergun H; Mamuk S; Köseoglu-Eser O; Melli M
    Ann Clin Lab Sci; 2012; 42(1):50-6. PubMed ID: 22371910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of ofloxacin activity against recent clinical isolates.
    Nani E; Anzivino D; Lavitola A; Lembo M; Covelli B
    J Chemother; 1989 Jul; 1(4 Suppl):145-6. PubMed ID: 16312345
    [No Abstract]   [Full Text] [Related]  

  • 27. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
    Deguchi T; Nakane K; Yasuda M; Shimizu T; Monden K; Arakawa S; Matsumoto T
    Int J Antimicrob Agents; 2010 Jun; 35(6):573-7. PubMed ID: 20226636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Levofloxacin].
    Azanza JR; Sádaba B; Quetglas EG; Escolar M
    Rev Med Univ Navarra; 1998; 42(4):220-5. PubMed ID: 10420933
    [No Abstract]   [Full Text] [Related]  

  • 29. [Levofloxacin: role and place in the treatment of infections of the lower respiratory tracts].
    Sinopal'nikov AI; Romanovskiĭ AG
    Ter Arkh; 2004; 76(11):51-6. PubMed ID: 15658538
    [No Abstract]   [Full Text] [Related]  

  • 30. [Present positioning of levofloxacin in chemotherapy of bacterial infections].
    Iakovlev VP
    Antibiot Khimioter; 2008; 53(9-10):3-5. PubMed ID: 19441643
    [No Abstract]   [Full Text] [Related]  

  • 31. Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
    Pallecchi L; Riccobono E; Montagnani F; Di Maggio T; Mantengoli E; Pollini S; Rossolini GM
    J Chemother; 2011 Oct; 23(5):308-9. PubMed ID: 22005066
    [No Abstract]   [Full Text] [Related]  

  • 32. [The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial].
    Cooperation Group for Phase IV Clinical Study of Levofloxacin
    Zhonghua Nei Ke Za Zhi; 2009 Jun; 48(6):492-6. PubMed ID: 19954047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration.
    George JM; Fiscella R; Blair M; Rodvold K; Ulanski L; Stokes J; Blair N; Pontiggia L
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):579-86. PubMed ID: 20977368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
    Hu BS; Fung CP; Liu PY; Lau YJ; Shi ZY; Lin YH
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct; 60(4):191-4. PubMed ID: 9439047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levofloxacin, a new quinolone antibacterial agent. An introductory overview.
    Hayakawa I; Furuhama K; Takayama S; Osada Y
    Arzneimittelforschung; 1992 Mar; 43(3A):363-4. PubMed ID: 1622431
    [No Abstract]   [Full Text] [Related]  

  • 38. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis.
    Cormican MG; Runyon BA; Jones RN
    J Chemother; 1995 Jun; 7(3):197-200. PubMed ID: 7562013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.